UTHR Posts Earnings, Shorts Stay Quiet

United Therapeutics reported Q3 results on November 4 with the stock up just 1.7% over the past week, a touch behind the median 2.6% gain for its closest correlated peers. Among that peer group, MNKD added 13.4% and KOD gained 8.3%, so the week's broad biotech bid lifted most names more aggressively than UTHR itself.

Short interest has stabilised after the dramatic covering wave of late October. Roughly 2.49 million shares remain borrowed, equal to 5.8% of the free float, essentially unchanged from the 2.47 to 2.50 million range that has held every day since October 26. That is a sharp contrast to the prior two weeks, when short positions ran at 3.6 to 3.7 million shares before collapsing in a single-week move that two previous notes identified as one of the most aggressive covers in the stock's recent history. The borrow market offers no tension: availability stands at 2,693%, meaning lendable shares dwarf those actually borrowed, and cost to borrow has ticked up 23% over the week to 0.53% but remains trivially low by any standard. What changed is the ORTEX short score, which dropped from roughly 49.6 on October 21 to 42.0 today, reflecting the reduced short positioning. Options confirm the residual bullish tilt. The put/call ratio is 0.44, nearly 1.5 standard deviations below its 20-day average of 0.65, keeping call-side demand well ahead of put buying. This is a looser version of the extreme call dominance seen through mid-October, but the direction is consistent.

The Street is broadly constructive, though with visible disagreement on how far the valuation can stretch. Following today's earnings, BTIG lifted its target from $728 to $768, maintaining a Buy, the most bullish published view in the recent analyst flow. JP Morgan trimmed its target by $15 to $695 last week but held its Overweight rating, and RBC similarly nudged its Outperform target down to $697 from $708. Those cuts look more like post-earnings housekeeping than a change in conviction. The mean target across the analyst group sits at $671, implying roughly 11% upside from the current $601. Goldman Sachs is the clearest outlier, having initiated in late September with a Sell and a $321 target, a figure the market has largely looked through given where the stock trades. The bull case rests on Tyvaso's durability in pulmonary hypertension and the potential for a material market expansion in IPF from April 2027, with peak non-risk-adjusted sales modelled at around $3.4 billion for Tyvaso in IPF and PPF. The bear case focuses on competitive pressure from Liquidia's Yutrepia in PAH, pipeline execution risk in TreSMI and ralinepag, and a downside SOTP value of $462 at an 8% discount rate. The PE multiple has expanded to 18.2x, up modestly on the month, while EV/EBITDA at 12.3x has actually eased over 30 days. Earnings yield ranks in the 81st percentile versus the broader universe, while EPS momentum over 30 days is exceptionally strong at the 91st percentile.

CEO Martine Rothblatt sold approximately 9,300 shares across multiple tranches on November 2, generating around $5.5 million in proceeds, all under a pre-arranged 10b5-1 plan. These are scheduled sales rather than discretionary market calls, and the significance scores filed with EDGAR are low. Net insider selling over the past 90 days totals around 54,000 shares worth approximately $32 million, the bulk of it attributable to the same plan-driven programme. On the institutional side, BlackRock added roughly 99,000 shares in the quarter to September 30, lifting its stake to 12.3% of shares outstanding. State Street added 108,000 shares to reach 4.4%. There are no activist positions on the 13D register, only passive Schedule 13G holders, and the largest disclosed individual stake is Rothblatt's own 1.6%.

Medicaid data from the Centers for Medicare and Medicaid Services adds one note of caution to the volume picture. Medicaid prescriptions across the company's portfolio have fallen for three consecutive quarters, with the most recent reading at 5,208 prescriptions for Q1 2026. Medicaid dollars reimbursed for the same period were $75.7 million, down 11% against Q1 of the prior year. This is a narrow slice of UTHR's total revenue base, and none of these datasets have been measured to lead the company's reported figures, so they are colour rather than signal. Retail attention, separately, registered a z-score of 4.69 against the stock's own prior 90-day history as of October 19, suggesting a meaningful spike in public interest around the earnings window.

The next scheduled earnings date is February 24, 2027. The question for the weeks ahead is whether the post-earnings PCR can hold near current call-heavy levels or drifts back toward the defensive readings above 0.90 that dominated September and early October, and whether the stabilised short base of 2.5 million shares begins to creep back toward the 3.6 million level that preceded last month's covering wave.